AdvaMed Accel – 2019 Achievements

- Winning full and permanent repeal of the medical device excise tax, saving our industry nearly $2 billion annually.

- Accomplishing key Medicare payment reforms, and improved coding processes, to support medtech innovation and speed patient access to breakthrough products and other life-changing new treatments and cures.

- Ensuring effective implementation of key provisions, which we supported as part of the FDA user fee agreement and the 21st Century Cures Act, as well as regulatory reforms in the FDA Reauthorization Act, to help accelerate patient access to innovation.

- Advocating through AdvaMed Accel for legislation and administrative rule-making that promotes investment in small firms, advancing initiatives that bring together a wider range of stakeholders in the innovation ecosystem – including academic institutions, and engaging the investment community directly for the benefit of small companies.

- Addressing increased regulatory activity surrounding ethylene oxide sterilization while educating stakeholders on its importance and bolstering our industry’s reputation for providing safe and effective health care solutions.

- Addressing ongoing global challenges, including issues surrounding implementation of new device and diagnostics regulations in Europe, the trade war with China, and volume-based procurement in China’s provinces.

- Achieving key international objectives, such as improvements in regulatory processes in China and Brazil, prevention of centralized pricing across China, mitigation of reimbursement cuts in Japan, pro-innovation provisions in the U.S.-Mexico-Canada free trade agreement, and progress toward stopping price controls in India.

- Unveiling AdvaMed’s Center for Digital Health as a flagship advocacy platform to advance digital health policy, support and promote the contributions of our industry to data-driven health care, and assert or thought leadership on emerging issues such as data privacy.

- Launching our MedTech Information Sharing and Analysis Organization, in line with our cybersecurity principles, to provide a safe space for the medtech industry to share cybersecurity information. We also achieved inclusion by FDA of key industry priorities in planned revised draft guidance on premarket cybersecurity.

- Exempting our industry from new burdensome and redundant state-level data privacy requirements in California and several other states, leading a national effort to address
similar data privacy legislation in other states, and pushing back against inappropriate state-based “Right to Repair” legislation.

- Advancing new safe harbors to the U.S. anti-kickback statute to enable more expansive and patient-centric value-based payment arrangements, civil justice and litigation reform, implementation of a comprehensive refresh of AdvaMed’s U.S. Code of Ethics and increased global harmonization of high-standard codes.

- Leading pro-innovation diagnostics regulatory reform efforts in concert with lab, patient and provider organizations, including through support of stakeholder processes on the Hill to refine bipartisan legislation poised for introduction in the House and Senate.

- Securing passage of bipartisan legislation (the LAB Act) through AdvaMedDx and in partnership with laboratories, aimed at ensuring more accurate Medicare reimbursement rates for diagnostics.

- Creating AdvaMed’s biggest and best-ever annual conference in Boston in September. The MedTech Conference achieved double-digit percentage growth for the second year in a row, with over 3,300 attendees representing more than 1,400 companies and stakeholder groups from 39 countries.

- Rolling out our new patient engagement platform, The Story of Medtech, to provide a forum where our strongest advocates – patients – can share their stories of how they have benefited from the innovations your companies produce.

- Debuting our AdvaMed Advance initiative – at a special summit in September – to promote inclusion and diversity in the medtech industry, share best practices and collaborate on ways to make our industry the most diverse, inclusive and innovative in the world. This included creation of a framework to facilitate industry development of company-specific workplans and evaluate our progress. During the year, we also signed the CEO Action for Inclusion pledge to advance diversity and inclusion in medtech.